SLC5A2 and hydrops fetalis: Additionally, and according to the American Diabetes Association (ADA), SGLT2 inhibitors are the first-line agents for pharmacological intervention in the treatment of type 2 diabetes mellitus (T2DM), especially in patients who are diagnosed with heart failure (HF) [12,13].